Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Files ProQuad MMR/Varicella Combo Pediatric Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

Company expects action on the BLA for a combination of its M-M-R II and Varivax vaccines by "early July" 2005. Three additional Merck vaccines are slated for submission over the next year, including agents for HPV and shingles.

You may also be interested in...



ProQuad Vaccine BLA Review Extended To September

FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30

ProQuad Vaccine BLA Review Extended To September

FDA has extended its review of Merck's measles, mumps, rubella and varicella vaccine ProQuad by three months until Sept. 30

Varicella Vaccine Routine Two-Dose Regimen Not Recommended By CDC Advisory Committee

The Centers for Disease Control & Prevention Advisory Committee on Immunization Practices declined to recommend routine second-dose varicella vaccination June 30

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel